Rajwant Sodhi Sells 1,350 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) insider Rajwant Sodhi sold 1,350 shares of ResMed stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $144.38, for a total value of $194,913.00.

Shares of RMD stock opened at $143.25 on Thursday. The company has a market cap of $21.21 billion, a P/E ratio of 39.12, a PEG ratio of 2.82 and a beta of 0.41. The stock has a 50 day simple moving average of $135.58 and a two-hundred day simple moving average of $125.55. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.46 and a current ratio of 2.11. ResMed Inc. has a fifty-two week low of $90.64 and a fifty-two week high of $149.96.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.06. The business had revenue of $681.06 million during the quarter, compared to the consensus estimate of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The firm’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.81 earnings per share. On average, research analysts predict that ResMed Inc. will post 4.04 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a $0.39 dividend. The ex-dividend date is Wednesday, November 6th. This represents a $1.56 dividend on an annualized basis and a yield of 1.09%. ResMed’s payout ratio is currently 42.86%.

RMD has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, October 25th. UBS Group raised ResMed from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $122.00 to $140.00 in a research note on Monday, July 29th. Goldman Sachs Group raised ResMed from a “neutral” rating to a “buy” rating in a research note on Monday, July 29th. Finally, ValuEngine lowered ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. ResMed currently has a consensus rating of “Buy” and an average target price of $121.50.

A number of hedge funds have recently modified their holdings of RMD. Westside Investment Management Inc. bought a new stake in ResMed in the second quarter worth approximately $26,000. Squar Milner Financial Services LLC increased its holdings in ResMed by 342.9% in the third quarter. Squar Milner Financial Services LLC now owns 217 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 168 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in ResMed in the second quarter worth approximately $40,000. CSat Investment Advisory L.P. increased its holdings in ResMed by 97.0% in the second quarter. CSat Investment Advisory L.P. now owns 388 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 191 shares in the last quarter. Finally, AdvisorNet Financial Inc increased its holdings in ResMed by 26.0% in the third quarter. AdvisorNet Financial Inc now owns 392 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 66.45% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Recommended Story: What is the formula for the cash asset ratio?

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.